Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1250 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Dr Boreham's Crucible: Cynata Therapeutics

CAS Group:
'Australian Biota Investors Should Oppose Aviragen Merger'

Varian Offers $1.6b For Sirtex
- Dr Boreham's White Hot Crucible

2017 - The Year In Review
- CEO, Chairman, Kamikaze of the Year; Capital Raisings

Rhythm Bio $9m IPO For Bowel Cancer Blood Test 

Telix $50m IPO Up 25% For Molecular Targeted Cancer Radiation 

Living Cell Tumbles 89% On NTCell Parkinson's Results

Biotech Daily Editorial - Selective Briefings 

Biotech Revenue Up 194% In 8 Years To $1.4b

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Novartis Buys Spinifex For $916m



January BDI-40 Up 4%, ASX200 Down 0.4%,
Big Caps Up 5%, NBI Up 7%

 Sirtex Up 66%, Dimerix 25%; Reva Down 29%, Prana 24%


Feb 1, 2018

Taking a bet on the three Big Caps of Cochlear, CSL and Resmed (which are not included in the Biotech Daily Top 40 Index) 12 months ago would have returned smart investors a 32.5 percent gain, and that’s not including dividends.
The BDI-40 wasn’t too shabby in the 12-month period either, up 20.6 percent compared to the ASX200’s 7.4 percent with the Nasdaq Biotechnology Index (NBI) up 23.3 percent.
In January, the BDI-40 improved 4.4 percent, the Big Caps were up a collective 5.2 percent and the NBI rose 6.9 percent, while the ASX200 fell 0.4 percent.
The BDI-40 saw small falls and rises in January, but was saved by Sirtex jumping $610 million, with Clinuvel, Medical Developments and Starpharma at record levels.
Seventeen of the BDI-40 companies were up, 22 fell and two were unchanged.
Sirtex was the best, up 66.2 percent on the Varian $1.6 billion bid, followed by Dimerix up 25 percent from a low base to $15 million, Viralytics (17.5%), Starpharma (16.1%), Benitec (14.6%), Clinuvel (8.7%) and Medical Developments (6.9%).
Reva led the falls, down 28.6 percent to $200 million, followed by Prana (23.7%), Osprey (23.0%), ITL (22.7%), Impedimed (21.4%), Factor Therapeutics (18.9%) and Admedus.
Both CSL and Resmed hit record market capitalizations with Cochlear slightly below its previous all-time high, with Resmed up 14.0 percent to $17,819 million, CSL up 3.6 percent to $66,221 million and Cochlear up 1.5 percent to $9,997 million.
The 15 Cannabis Corner companies climbed 31.7 percent to $1,575 million with Cann up 21.7 percent to $331 million, Medlab up 23.4 percent for the month and 123.1 percent for the year, Botanix up 116.0 percent in January to $54 million and Auscann up 119.4 percent to $226 million in the month.

In the US, Protagonist was up 6.6 percent to a record $581 million, Redhill recovered 17.1 percent and Aviragen held steady at $28 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Jan 31, 2018 
BDI-40 v S&P ASX200 Jan 31, 2017 to Jan 31, 2018 
Big Caps (Cochlear, CSL, Resmed) Year To Jan 31, 201


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Jan 31, 2018


* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan, Polynovo,
   Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: